State Street Corp Increases Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

State Street Corp grew its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 101.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 821,131 shares of the company’s stock after purchasing an additional 413,425 shares during the period. State Street Corp owned approximately 2.77% of Dianthus Therapeutics worth $22,483,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of DNTH. Bank of New York Mellon Corp increased its stake in Dianthus Therapeutics by 860.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 80,935 shares of the company’s stock valued at $2,095,000 after buying an additional 72,509 shares during the period. HighVista Strategies LLC purchased a new stake in shares of Dianthus Therapeutics in the third quarter valued at about $542,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Dianthus Therapeutics by 142.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock valued at $4,543,000 after acquiring an additional 97,362 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Dianthus Therapeutics by 104.0% during the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after acquiring an additional 4,506 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after purchasing an additional 263,500 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Up 3.3 %

NASDAQ:DNTH opened at $23.80 on Monday. Dianthus Therapeutics, Inc. has a 52-week low of $7.75 and a 52-week high of $33.77. The stock has a fifty day simple moving average of $25.69 and a 200-day simple moving average of $26.64. The company has a market capitalization of $704.48 million, a PE ratio of -9.52 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. As a group, equities analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on DNTH shares. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Oppenheimer upped their price objective on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. TD Cowen initiated coverage on Dianthus Therapeutics in a research report on Friday. They issued a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $46.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.